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Age-relatedmacular degeneration (AMD), a progressive condition that is untreatable in up to 90%of patients,
is a leading cause of blindness in the elderly worldwide. The two forms of AMD, wet and dry, are classified
based on the presence or absence of blood vessels that have disruptively invaded the retina, respectively.
A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust
FDA-approved therapies. In contrast, there are no approved treatments for dry AMD. In this review, we
provide insight into the critical effector pathways mediating each form of the disease. A recurring theme
that spans most aspects of AMD pathogenesis is defective immune modulation in the classically immune-
privileged ocular haven. Interestingly, the latest advances in AMD research also highlight commonmolecular
disease pathways with other neurodegenerative disorders. Finally, the therapeutic potential of intervening at
known mechanistic steps of AMD pathogenesis is discussed.Introduction
Age-related macular degeneration (AMD) is a principal cause of
blindness in the United States and other industrialized nations.
An estimated 10 million Americans are afflicted with AMD
(Friedman et al., 2004), which is comparable in scope to the 12
million living with cancer (Hayat et al., 2007) or the 5 million
with Alzheimer’s disease (Brookmeyer et al., 2007). The preva-
lence of AMD steadily increases with age, affecting 2% of
the population at age 40, and one in four people by age 80
(Friedman et al., 2004). For reasons that are not fully understood,
AMD is more common in lightly-pigmented and female popula-
tions (Friedman et al., 2004). Treatment of AMD is largely an
unmet need: there are no FDA approved therapies except for
a small percentage of individuals with end-stage disease.
There are two types of AMD, the ‘‘dry’’ and ‘‘wet’’ forms. Dry
AMD is a chronic disease that usually causes some degree of
visual impairment and sometimes progresses to severe blind-
ness. In contrast, wet AMD affects only 10%–15% of AMD
patients, emerges abruptly, and rapidly progresses to blind-
ness if left untreated (Guyer et al., 1986; Wong et al., 2008).
Since AMD patients typically develop the dry form first, wet
AMD occurs on a background of dry AMD; as such, dry AMD
can be considered a risk factor or even precursor state for
wet AMD.
In the early stages of AMD, which is asymptomatic, insoluble
extracellular aggregates called drusen accumulate in the retina
(see Figure 1 in Bird, 2010). The late stage of dry AMD, which
is also known as geographic atrophy (GA), is characterized by
scattered or confluent areas of degeneration of retinal pigment
epithelium (RPE) cells and the overlying light-sensing retinal
photoreceptors, which rely on the RPE for trophic support. The
other late stage form of AMD, the wet form, is typified by
choroidal neovascularization (CNV) wherein newly immature
blood vessels grow toward the outer retina from the underlying
choroid. These immature blood vessels leak fluid below or within
the retina.26 Neuron 75, July 12, 2012 ª2012 Elsevier Inc.It is convenient to dichotomize the pathology of ‘‘wet’’ and
‘‘dry’’ forms of the disease based on the presence or absence,
respectively, of CNV. However, as an understanding of AMD
pathogenesis improves, emerging evidence indicates that sig-
nificant overlap exists in the underlying mechanisms of these
seemingly disparate clinical conditions. In spite of this apparent
overlapping pathophysiology, the two forms of AMD are indeed
somewhat clinically distinct: that is, effective treatment of wet
AMD does not typically ameliorate the dry AMD component.
Clearly, further clarification of the overlapping and unique
processes that lead to wet and dry pathology will be essential
for future advances in the prevention and treatment of AMD.
The Retina
In Health
For a review of structural features in the healthy retina versus the
AMD-afflicted retina, the reader is referred to excellent reviews
elsewhere (Bird, 2010; Rattner and Nathans, 2006). The features
of a healthy ocular fundus is shown in Figure 1A. Relative to the
surrounding peripheral retina, the macular region has a high
density of photoreceptors. As such, the macula subserves
central vision and acuity that enables resolution of fine details,
such as edges or borders. The retina consists of multiple cell
layers that form an interdependent anatomical and metabolic
network. Other notable features of the retina include: the selec-
tively permeable blood-retinal barrier (Cunha-Vaz, 2004), the
greatest oxygen consumption per weight of any organ in the
body (Warburg, 1928), and immune privilege (Streilein, 2003).
In AMD
Geographic Atrophy. A representative eye with GA is shown in
Figure 1B. AMD primarily affects the macular region of the
retina, with relative sparing of the surrounding peripheral retina.
AMD is defined by confluent regions of drusen, which are
multicomponent, heterogeneous aggregates that lie both
external and internal to the RPE cells (Klein et al., 2008; Zweifel
et al., 2010). The emergence and ‘‘growth’’ of drusen occurs
Figure 1. Fundus Photographs in Health
and in AMD
(A) The ocular fundus of a healthy eye, showing
normal pigmentation and retinal blood vessels.
(B) The late-stage dry form of AMD, known as
geographic atrophy. Note large regions of depig-
mentation, especially in themacula, which is at the
center of the image.
(C) In wet AMD, leaky blood vessels from the
choroid invade the overlying retina.
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dysfunction accompany underlying drusen (Johnson et al.,
2005), although the cause-effect relationship of drusen and
retinal degeneration (which may be reciprocal) is not fully
understood.
Choroidal Neovascularization. A representative eye with CNV
is shown in Figure 1C. CNV also primarily affects the macula.
If left untreated, it can lead to severe blindness with scarring
within several months. Assessment of CNV is typically made
using fluorescein angiography or optical coherence tomography
to measure characteristic lesions with leakage of blood or
plasma proteins from immature choroidal blood vessels.
Introduction to the Mechanisms of AMD Pathogenesis
This review is focused on the mechanistic underpinnings of
AMD. Before delving into the molecular details of disease, we
will provide a short account of the success of mechanism-based
therapy in AMD.
From AMD Disease Mechanism to Approved Therapy
Understanding the molecular basis of disease empowers one to
translate such knowledge into clinical use. A stellar example of
mechanism-based therapy is antiangiogenesis treatment for
wet AMD. Ferrara’s cloning of vascular endothelial growth
factor-A (VEGF-A) in 1989 (Leung et al., 1989), combined with
knowledge derived from the pioneering work by Folkman and
other investigators in the field of oncology (Folkman, 1995),
revealed the centrality of VEGF in vascular biology. These
seminal contributions enabled Ferrara et al. to develop the first
anti-VEGF-A treatment, the monoclonal antibody Avastin (beva-
cizumab; Genentech), which received FDA approval for cancer
treatment in 2004. Subsequently, the importance of VEGF-A in
ocular neovascularization was validated (Adamis et al., 1994;
Aiello et al., 1994). Coupled with the identification of VEGF-A in
surgically obtained CNV specimens from humans with AMD
(Frank et al., 1996; Kvanta et al., 1996; Lopez et al., 1996), the
development of anti-VEGF-A agents to treat neovascular AMD
quickly followed suit.
FDA-approved therapies for CNV emerged in 2004 (Macugen;
pegaptanib sodium; Eyetech/Pfizer) (Gragoudas et al., 2004) and
2006 (Lucentis; ranibizumab; Genentech) (Brown et al., 2006;
Rosenfeld et al., 2006). Although off-label bevacizumab is not
FDA approved for use in neovascular AMD, it has assumed an
equal footing with ranibizumab in clinical care because it has
similar efficacy yet costs substantially less (Martin et al., 2012).
Most recently, in 2011 Eylea (VEGF-TRAP-Eye; aflibercept;
Regeneron) (Economides et al., 2003) received FDA approval
for treatment of CNV.Today, anti-VEGF-A therapy for CNV dramatically improves or
stabilizes vision in the vast majority of patients (Martin et al.,
2011). This phenomenal clinical success has set the stage for
treatment of other ophthalmologic maladies (e.g., diabetic
macular edema, retinal vein occlusion, iris or corneal neovascu-
larization, uveitis) (Ciulla and Rosenfeld, 2009) and extraocular
diseases (e.g., neoplasms, heart disease, neurodegeneration)
(Carmeliet, 2005) that share a common VEGF-A-dependent
pathway of angiogenesis. While antiangiogenic therapy for wet
AMD benefits many patients and typifies the success of mecha-
nism-based translational medicine, there are no approved treat-
ments for the more common dry form of AMD and progress
toward the identification of molecular targets for this disease
subset remains constrained.
The RPE: At the Core of AMD Pathogenesis
Whereas the stepwise development of certain maladies (e.g.,
cancers) is relatively well-defined (Hanahan and Weinberg,
2011), no such hallmarks of disease progression have been
identified in AMD. Nonetheless, the literature abounds with
various implicated causes of disease. For want of a comprehen-
sive systems approach, one could navigate the numerous
avenues and permutations by which an ever-growing list of
mechanisms contribute to AMD pathology. Indeed, such an
approach has been emphasized in previous reviews (Ambati
et al., 2003a; Bird, 2010; Patel and Chan, 2008; Rattner and
Nathans, 2006; Zarbin, 2004). Instead, since diverse etiologies
may contribute to an AMD phenotype, we advance three models
of disease mechanism that emphasize critical, nonredundant
effector pathways.
In each of these models, the RPE is the fulcrum of AMD
pathogenesis. In general, although interindividual heterogeneity
exists, RPE dysfunction and atrophy precedes the latter stages
of AMD (GA or CNV). The RPE integrates numerous stimuli to
define its own health, while also receiving and broadcasting
signals to and from the retinal microenvironment. The capacity
of the RPE to modulate diverse pathways of AMD pathogenesis
can be gleaned from RNA transcriptome analyses of human
AMD donor eyes (Booij et al., 2010; Newman et al., 2012) and
in vitro RPE cells (Strunnikova et al., 2010). Importantly, human
AMD samples display significant interindividual variation in
RPE transcript expression, which supports the concept that
heterogenic stress responses underlie a categorical AMD
phenotype. Genome-wide stress-response transcriptome and
proteome assays have begun to catalog the effect of specific
AMD-associated stresses (Kurji et al., 2010), and age-related
changes in retinal molecular composition (Cai and Del Priore,
2006; Glenn et al., 2011) on whole-genome RPE geneNeuron 75, July 12, 2012 ª2012 Elsevier Inc. 27
Figure 2. The Immunovascular Axis of Wet
AMD
There are numerous overlapping proangiogenic
mechanisms that underlie wet AMD, many of
which involve the intersection of immune and
vascular systems. See corresponding text in
Review.
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applied to a multitude of AMD-associated stresses, the pooled
results of these studies could reveal common protective and
deleterious RPE gene responses and would also help clarify
the key molecular drivers of disease. Subsequently, the manipu-
lation of critical pathways in stress-function assays and animal
models of AMD could create new avenues of therapeutic
strategy and augment existing knowledge garnered from
focused investigations of specific pathways or sets of genes.
An important route of communication and recurring theme in
AMD pathology is the crosstalk of RPE with immune and
vascular systems. This ‘‘immunovascular axis’’ drives CNV;
however, whether this network modulates RPE cell viability is
less clear. Although the vitality of the RPE cell is paramount
to retinal health, it is also true that perturbations in other
tissues, for example, the choroid, Bruch’s membrane and
photoreceptors, are important burdens on the retinal microen-
vironment. Nevertheless, the critical event in AMD pathogen-
esis, from which there is no return, is RPE dysfunction and
degeneration.
Molecular Mechanisms of Neovascular AMD: RPE
Stress and the Immunovascular Axis
Our first of three paradigms of AMD molecular pathogenesis is
an integrated view of CNV that is supported by an abundance
of successful therapeutic efforts in human and animal models.
Figure 2 details the molecular mechanisms of CNV pathogen-
esis. As will be discussed, the RPE response to heterogeneous
stressors is an integral process in CNV. RPE-independent mech-
anisms of CNV may also exist, though such pathways are not28 Neuron 75, July 12, 2012 ª2012 Elsevier Inc.incongruent with the centrality of RPE
immunovascular signaling in CNV.
RPE Vascular Response
Blockade of VEGF-A, a potent proangio-
genic messenger, is the basis of available
therapies for neovascular AMD. The
two major pathways by which the RPE
produces and secretes VEGF-A are in
response to complement (Nozaki, Raisler
et al., 2006; Rohrer et al., 2009; Figure 2)
and oxidative stress (Pons and Marin-
Castan˜o, 2011; Figure 2). Simply defined,
oxidative stress is the oxidation of cellular
macromolecules, and the complement
system is a set of about 30 proteins that
are an important component of the innate
immune response to microbes (Bradley
et al., 2011). If left unregulated, activation
of complement proteins can directlydamage host tissue and recruit immune cells to the vicinity of
active complement activation. It is presumed that protection
against complement is achieved through a variety of comple-
ment regulatory molecules that are expressed in and localize
to the retina (Anderson et al., 2010).
These primary stresses may act independently to induce
angiogenesis, but they also synergize. For example, oxidative
stress potentiates complement-induced RPE secretion of
VEGF-A (Thurman et al., 2009). Besides VEGF, other directly
vasculogenic molecules (i.e., that act on endothelial cells;
Figure 2) are also secreted by the RPE in response to activated
complement (Fukuoka et al., 2003) and oxidative stress (Higgins
et al., 2003). Many such RPE-elaborated cytokines have been
identified in human and experimental CNV specimens (Amin
et al., 1994; Bhutto et al., 2006; Grossniklaus et al., 2002; Lopez
et al., 1996). Analysis of human tissue is an important counter-
part to information derived from experimental disease models,
although it must be noted that these human data are somewhat
limited by small sample sizes and also subject to variability
introduced in part by technical and logistical challenges of post-
mortem tissue isolation.
Still, the RPE need not be the only source of proangiogenic
factors, which could originate from various immune cells or
other cell types (Figure 2). Importantly, the focus of the present
model is to display the multiple, redundant pathways via which
CNV could be augmented. We emphasize the RPE as a central
player in CNV in order to demonstrate two key mechanistic
points: (1) The potential for multiple distinct stresses to converge
to produce a common (proangiogenic) effect (Figure 2) and (2)
the diversity of response molecules produced by the RPE that
Neuron
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nated CNV treatment, it is reasonable to expect that future
endeavors will lead to CNV therapeutics that block other angio-
genesis-promoting molecules (Noe¨l et al., 2007).
RPE Immune Response
A proinflammatory retinal milieu, which is promoted by RPE
response to heterogeneous stresses, appears to be a keymodu-
lator of CNV development and progression. The RPE regulation
of the complement system here too plays an important role:
besides inducing RPE secretion of proangiogenic VEGF, active
complement factors C3a and C5a are potent chemotactic
agents and recruit leukocytes to the choroid (Nozaki et al.,
2006; Figure 2). Furthermore, oxidative stress of the RPE by
photo-oxidation products activates complement (Zhou et al.,
2006), and an oxidative damaged-induced autoimmune reaction
results in complement deposition in the retina (Hollyfield et al.,
2008). Thus, just as the RPE secretes diverse direct effectors
of angiogenesis in response to heterogeneous stressors, there
are multiple pathways by which the RPE can regulate the retinal
immune-landscape, which in turn can regulate neovasculariza-
tion in AMD.
In particular, in CNV, the macrophage is the king of vascular-
modifying immune cells that are attracted to the retina in disease;
an increase in the number of retinal macrophages is a hallmark
of CNV (Cherepanoff et al., 2010; Grossniklaus et al., 2000;
Skeie and Mullins, 2009; Figure 2). However, whether macro-
phages are critical for CNV development or progression is not
clear—their increase in CNV could either represent an exacer-
bation of disease or a compensatory vascular-dampening
response. In support of their proangiogenic properties, inhibition
of monocyte migration to the retina reduced CNV in a laser-
induced mouse model of disease (Espinosa-Heidmann et al.,
2003; Sakurai et al., 2003). In contrast, in a non-injury mouse
model of AMD, mice that are genetically deficient for either
CCR2 or its cognate ligand (CCL2)—and consequently possess
defects inmacrophagemobilization—develop choroidal neovas-
cularization (Ambati et al., 2003b), suggesting that macrophages
somehowalso protect against CNV (Ambati et al., 2003b;Molday
et al., 2000). The reader is directed to an excellent review of the
role of macrophages in CNV (Skeie and Mullins, 2009). Given
the available evidence, the most likely role for macrophages in
CNV is determined by local macrophage-polarizing factors (Kelly
et al., 2007; Patel et al., 2008). Indeed, work in tumor biology has
revealed complex local regulation of macrophage vascular-
modifying activity. In light of current interest in immune-modu-
lating interventions for CNV (Wang et al., 2011b), the particular
microenvironmental influences governing macrophage activity
in CNV remains an area of needed research.
The potential for immune contribution to CNV begs several
salient questions about disease mechanism. For one, if certain
proangiogenic factors are also proinflammatory, does antiangio-
genesis therapy achieve its clinical effect by reducing both
direct vascular and indirect immune effects? Among the many
factors that control macrophage chemotaxis, VEGF-A has
awell-defined role in recruitment of proangiogenicmacrophages
(Cursiefen et al., 2004). Therefore, it is reasonable to expect that
anti-VEGF therapy might reduce macrophage infiltration of the
retina in CNV.On the contrary, bevacizumab treatment of CNV dramatically
increased the number of retinal macrophages within human
neovascular membranes (Tatar et al., 2008). Subsequent work
showed that blockade of VEGF-A increased leukocyte-endothe-
lial adhesion, which could explain the increase in retinal macro-
phages following anti-VEGF-A therapy (Walshe et al., 2009). In
addition, compensatory elevation in VEGF-A levels following
anti-VEGF-A therapy (Willett et al., 2005) might promote inflam-
matory cell recruitment. These findings raise the following ques-
tion, the answer to which has important therapeutic implications:
What is the ratio of pro- and antiangiogenic macrophages that
accumulate after anti-VEGF-A treatment? If the proportion or
relative activity of proangiogenic macrophages increased
following anti-VEGF treatments, this finding could explain the
tachyphylaxis (desensitization) that occurs with multiple anti-
VEGF-A treatments (Forooghian et al., 2009). In that case, the
selective inhibition of proangiogenic macrophages would be an
appealing adjunct to anti-VEGF therapy. This is in contrast to
the current, broad-spectrum use of immunosuppression in
AMD, which does not target a certain immune cell or subtype.
Microglia are another immune cell type that might modulate
human CNV pathogenesis. These resident retinal macrophages
accumulate in the subretinal space in a CX3CR1-deficient
mouse after light-induced and aging models of retinal degener-
ation; the accumulation of microglia in these mice appears
to exacerbate laser-induced CNV (Combadie`re et al., 2007).
The CX3CR1/, CCL2/, CCR2/ mouse models of AMD
predominantly exhibit defects in microglia and macrophage
function (reviewed in Raoul et al., 2010). When compared to
mouse models deficient in either one of these chemokine recep-
tors, a double-knockout mouse genetically deficient for both
CX3CR1 and CCR2 produced a more penetrant, and earlier-
onset, spontaneous phenotype of retinal lesions similar to those
seen in dry AMD; also, a subset (15%) of mice spontaneously
developed choroidal neovascularization (Tuo et al., 2007).
However, while macrophages accumulate in human CNV
membranes, it is not known whether microglia do, too. In the
largest histopathologic characterization of microglia in AMD to
date, which observed microglia at various stages of AMD
pathology, there was a change in microglia morphology, but
not number, in AMD compared to nondiseased retinas (Penfold
et al., 1997). The precise functional ramifications of such altered
microglia morphology remain to be elucidated. Very recently
it has been claimed that many of the early-onset retinal degener-
ative phenotypes observed in the CX3CR1/ mice are attribut-
able to the fact that thesemice were generated on the C57BL/6N
background, which contains the rd8 retinal degeneration muta-
tion of the Crb1 gene (Mattapallil et al., 2012). However, the
CCL2/ and CCR2/ mice were generated on the C57BL/6J
background, which does not contain the rd8 mutation, and
develop retinal findingsmanymonths later than rd8mice (Ambati
et al., 2003b). Therefore, the retinal phenotype in CCL2/ and
CCR2/ mice are attributable to microglia/macrophages and
point to an important role for these myeloid-derived cells in
maintaining retinal homeostasis.
Immune cells besides macrophages and microglia could also
modify CNV (Figure 2). The cellular infiltrate in experimental
CNV is a motley band of circulating and resident, immune andNeuron 75, July 12, 2012 ª2012 Elsevier Inc. 29
Figure 3. Toxic Accumulations in Dry AMD
Left: dry AMD is characterized by the accumula-
tion of various types of retinal debris. Right: the
interplay of reactive oxygen species and autoph-
agy in disease pathogenesis is an emerging theme
in AMD and other common neurodegenerations.
See corresponding text in Review.
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were not classified (Espinosa-Heidmann et al., 2005); future
work could provide a comprehensive assessment of the com-
position of cellular infiltrate in human CNV specimens. Indeed,
other myeloid-derived immune cells are increasingly implicated
in vascular modification in other systems. For example, neutro-
phils and other nonmacrophage immune cells increase in cancer
tumors following anti-VEGF-A treatment (Ferrara, 2010). In fact,
neutrophils contribute to CNV pathogenesis in experimental
animal models (Sun and Nathans, 1997; Zhou et al., 2005); it
would be interesting to learn whether neutrophils are present in
human CNV specimens or the retinal immune infiltrate that
follows anti-VEGF treatment. As is the case with macrophages,
it is becoming increasingly clear that subsets of other immune
cells can have dramatically different effect on vasculature (Sica
et al., 2008). Thus, a full understanding of the immunopathology
of CNV will require an assessment of all potential vascular-
modifying immune cells, and their subsets, in health, disease,
and following therapeutic intervention.
Looking forward, the mechanism of immune suppression in
reducing CNV requires extensive clarification. While it is known
that steroids reduce the net proangiogenic cytokine secretion
by the RPE (Tong et al., 2006), the effect of immune suppressive
agents on immune cell activity (Ehrchen et al., 2007) in CNV
remains undefined. As such, targeted immune suppression or
modulation of specific immune cells is one avenue of research
that could yield valuable therapeutic advances in CNV.
Toward a Model of Dry AMD
In contrast to wet AMD, clinical success in treating dry AMD
remains elusive. The molecular hallmarks of dry AMD are toxic
accumulations, either within the RPE cell or at the RPE-BrM
interface (Figure 3). As such, dry AMD may be thought of as an
insidious form of a metabolic storage disease. Two approaches
to reducing these lingering burdens are (1) preventing their30 Neuron 75, July 12, 2012 ª2012 Elsevier Inc.formation or (2) removing them after
formation. Attempts to prevent RPE
damage have been unsuccessful,
although the removal of toxic accumula-
tions as a therapeutic strategy remains
largely unexplored. In search of the
‘‘holy grail’’ of AMD treatment, we will
discuss two emerging conceptual frame-
works that offer fresh research avenues
and the promise to help fill the gaping
therapeutic void in dry AMD.
The ‘‘Damaged Goods’’ Model
Simply put, AMD and other neurodegen-
erative disorders occur when a particularcell or group of cells dies. Although the distressed cells in
each disease are often different, their pathologies share several
themes. For one, some have recognized that common neurode-
generative diseases of aging, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS),
and Huntington’s disease (HD), are similar in that they accumu-
late mitochondrial defects (Lin and Beal, 2006). We propose
adding AMD to this list. The mitochondrial defects observed in
the RPE of AMD eyes include DNA mutations, impaired struc-
tural integrity, and defective mitochondrial function (Figure 3).
The consequences of damaged mitochondria can be dire: in
particular, diminished energy production and imbalance of
pro- and antiapoptotic signals lead to cell death (Lin and Beal,
2006). Mitochondrial damage also leads to increased ROS
production, which, in turn, may tarnish other key cellular compo-
nents.
Besides defective mitochondria, other toxins accumulate in
AMD and other common neurodegenerative diseases. For
example, an excessive amount of ‘‘lipofuscin,’’ which is nonde-
gradable debris that accumulates in the RPE with age, is associ-
ated with AMD (Schmitz-Valckenberg et al., 2009). In the
presence of light, lipofuscin forms ROS and is toxic to RPE
cells (Winkler et al., 1999). Analogous lipofuscin-like substances
that occur in other neurodgenerations include beta-amyloid or
tau-protein inclusions in Alzheimer’s disease, huntingtin protein
in Huntington’s disease, Lewy bodies in Parkinson’s disease,
and nonamyloid aggregates in amyotrophic lateral sclerosis. In
general, mtDNA dysfunction precedes the accumulation of these
substances (Lin and Beal, 2006).
The various forms of neurodegeneration each can be
described in terms of such signature pathologies, which is likely
the result of cell or tissue-specific stresses or response to stress.
The diverse microenvironments and unique biological flux
experienced in these heterogeneous cell types make it difficult
to assign common inciting stressors or stress responses—which
Neuron
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Still, mitochondrial dysfunction appears to be a common
co-pathology of neurodegeneration, and it is an appealing
concept that the persistence of damaged mitochondria and
other cellular detritus represents a common node at which point
myriad stressors converge. In this respect, we view AMD as a
disease that has many potential upstream causes or damage-
inducing stimuli that funnel into downstream and less-redundant
pathways. To date, nearly all attempts to revert AMD have
focused on preventing toxin accumulation; yet if there are
diverse causes of toxin formation, then it is worth defining the
potential therapeutic role of filtering the cellular milieu at the
confluence, rather than the source, of the disease pathogenesis
watershed.
Autophagy
Cells are equipped with machinery to discard toxic accumula-
tions. In a self-cleansing process called macroautophagy, the
cell can be rid of large, damaged cellular contents such as organ-
elles or proteins. Here forward we will use the term ‘‘autophagy’’
in place of ‘‘macroautophagy,’’ although it is important to recog-
nize that other forms of autophagy also exist (Klionsky, 2007). In
essence, autophagy of the mitochondria (a.k.a. ‘‘mitophagy’’)
and other cellular debris could rejuvenate cells by disposing of
defunct organelles, a concept which has been reviewed for
AMD (Mitter et al., 2012) and other neurodegenerative disorders
(Wong and Cuervo, 2010). Future work should address several
basic questions about this cell survival mechanism in AMD,
such as whether the various animal models of disease undergo
autophagic changes, and if autophagy-modulating compounds
can reverse experimental disease.
Damage Control
Since ROS damage is a common feature of neurodegenerative
diseases, anti-oxidant supplementation has been an area of
intense therapeutic investigation. Unfortunately, this approach
has failed to ameliorate manifest neurodegenerative disease
(Boothby and Doering, 2005; Evans, 2008; Shen and Ji,
2010). Indeed, a cocktail of antioxidants has not shown benefit
in progression to advanced dry AMD, although they were re-
ported to have a small effect in reducing rate of progression
to CNV (Age-Related Eye Disease Study Research Group,
2001). Given the widespread shortcomings of antioxidant
supplementation for dry AMD and other diseases in clinical
trials, a new wave of neurodegeneration research focuses,
appropriately, on combating lingering oxidative damage in an
effort to renew cellular robustness.
Ironically, ROS damages the cellular components that are
disposed by autophagy, yet ROS are also critical for induction
of autophagy (Scherz-Shouval et al., 2007). The counterpoint
is also true: It has been shown that antioxidants inhibit auto-
phagy (Underwood et al., 2010). Thus, in theory, flooding the
retina with anti-oxidants, which did not significantly prevent
progression of or vision loss from AMD by main outcome
measures (Age-Related Eye Disease Study Research Group,
2001), could be counterproductive to removing biological
garbage. The interplay of ROS and autophagy is expansive
and has been reviewed elsewhere (Szumiel, 2011). Autophagy
may also regulate RPE health by reducing cytotoxicity that is
secondary to a primary insult. For example, a mitochondrionthat has been damaged by ROS overproduces even more
ROS; therefore, mitophagy would reduce both the root and
downstream ROS burden (Zhou et al., 2011).
DICER1: The Common Thread?
Until now, we have discussed the mechanistic underpinnings for
some of the many identified RPE stressors. Yet, because these
injurious agents are so vast and heterogeneous, the ‘‘RPE
stress’’ that they cause is necessarily a nebulous term. The
cumulative burden on the RPE may, or may not, converge to
a single pathway that determines RPE cell viability. Thus, in
contrast to wet AMD—in which VEGF-A is the linchpin of blood
vessel growth—the search for a single molecule or pathway
that is critical in preventing RPE cell death in dry AMD remains
elusive. Therapeutic attempts to promote the robustness of the
RPE would be bolstered by the discovery of a common node
that tied together at least some of the seemingly disparate
stressors that are implicated in AMD pathogenesis. Is there an
integrative hub of RPE viability that coordinates the effect of
multiple, redundant stressors?
The activity of the enzyme DICER1 is sufficiently broad-reach-
ing that it is an attractive candidate as a choreographer of retinal
health and homeostasis (Figure 4). Specifically, the literature
supports an emerging role for DICER1 in governing RPE cell
health and function via several mechanisms, including its influ-
ence on inflammation and global (coding and noncoding) RNA
expression. DICER1, a ribonuclease, was specifically reduced
in the RPE of GA patients (Kaneko et al., 2011); moreover, this
pathological decrease in DICER1 was accompanied by the
aberrant overabundance of the noncoding Alu RNA, which is
toxic to RPE cells. In that study, Kaneko et al. (2011) also present
a new disease model of GA: the genetic ablation or knockdown
of DICER1 in the mouse RPE.
The Alu RNAs that accumulate in DICER1 deficiency are
transcribed from Alu DNA sequences in the nuclear genome.
Sometimes described as ‘‘genomic parasites,’’ these 300 nt
DNA sequences constitute at least 11%of all genomic DNA (Bat-
zer and Deininger, 2002). Alus are retrotransposons, meaning
they ‘‘jump’’ around the genome by (1) transcription, (2) reverse
transcription, and (3) genomic integration at a new locus. The
deleterious effect of Alu sequences is often ascribed to a single
retrotransposition event; for example, an Alu sequence may
insert into a critical gene, thereby disrupting gene function
(Belancio et al., 2008). However, the mechanism of Alu RNA-
induced toxicity in GA appears to occur by a novel pathway.
Recent work has identified an innate immune complex called
the NLRP3 inflammasome as the response platform that
mediates Alu RNA-induced RPE cell death (Tarallo et al.,
2012). That study provided evidence of inflammasome activation
in the RPE of human GA donor eyes, and showed that in exper-
imental DICER1 deficit, activation of the NLRP3 inflammasome
by Alu RNA leads to RPE IL-18 secretion, which induces
MyD88-dependent RPE cell death. This finding solidifies the
central role of the RPE in AMD pathogenesis. Interestingly, to
date, NLRP3 inflammasome activation is almost exclusively
confined to immune cells, thereby presenting an identity crisis
for the RPE, which can now be redefined, in part, in terms of
its immune function.Neuron 75, July 12, 2012 ª2012 Elsevier Inc. 31
Figure 4. DICER1: Central Hub of the RPE
The miRNA-processing enzyme DICER1 is a key
determinant of RPE cell health. Several non-
canonical (miRNA-independent) roles for DICER1
have been described in AMD, including regulation
of inflammation and cytotoxic noncoding Alu
RNAs. See corresponding text in Review.
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one question remains unresolved: why do Alu RNAs accumulate
in the RPE of GA patients? Because DICER1 cleaves Alu RNA, it
is reasonable to expect that DICER1 deficit precedes Alu RNA
accumulation. Therefore, it is important to ask: why does
DICER1 decrease in GA? Recent studies show that a variety of
stresses can regulate DICER1 expression. It is possible that
multiple RPE insults implicated in AMD pathogenesis could
cause DICER1 to decrease (Wiesen and Tomasi, 2009). Interest-
ingly, general stresses such as heat shock, viral infection, or
translational inhibition also causes Alu to increase (Li and
Schmid, 2001). Future intersecting projects could determine
whether AMD-associated events (e.g., complement activation,
mtDNA damage, oxidation of lipofuscin) lead to DICER1 deficit,
Alu RNA accumulation and NLRP3 inflammasome activation.
One recent example of such work was the finding that comple-
ment C1q, which is present in human AMD drusen, can activate
the NLRP3 inflammasome (Doyle et al., 2012).
Do other neurodegenerative disorders also have a pathophys-
iologic decrease in DICER1? DICER1 is well known for its key
role in the biogenesis ofmiRNAs, which facilitate the degradation
or translational inhibition of most mRNAs (Friedman et al., 2009).
Indeed, miRNA deficiency occurs in diseased but not age-
matched controls in Alzheimer’s disease, Parkinson’s disease,
and Huntington’s disease (Christensen and Schratt, 2009;
Eacker et al., 2009); whether DICER1 levels are similarly
decreased in neurodegenerative diseases other than AMD
remains to be seen. Intriguingly, microarray data reveal a reduc-
tion of DICER1 in the hippocampus of human Alzheimer’s
disease donor tissue (Blalock et al., 2011).
Interestingly, in contrast to the proposed role of DICER1
deficit in other disorders, the phenotypic outcome of DICER1
deficiency in the experimental model of AMD was independent32 Neuron 75, July 12, 2012 ª2012 Elsevier Inc.of miRNA perturbation. Instead, the
accumulation of Alu RNA was the major
driver of RPE toxicity. Based on this
finding, it will be interesting to see if Alu
RNA plays a role in the expanding
compendium of diseases that are defined
by DICER1 deficit.
Even though perturbation of miRNA
maturation appeared to be dispensable
for RPE cell health in the DICER1 deficit-
induced animal model of AMD, miRNAs
might still play a key role in determining
the cell viability of RPE. Importantly, in
the Kaneko et al. study, the mice were
not exposed to the various stressors
implicated in AMD—perhaps miRNAperturbation in AMD serves a key role only when coupled with
some other RPE insult. Notably, miRNA expression regulates
AMD-associated events, including inflammation (O’Neill et al.,
2011) and angiogenesis (Sen et al., 2009) (Figure 4).
Finally, DICER1 regulation of gene expression might also be
achieved by miRNA-independent mechanisms, such as Dicer-
dependent chromatin modifications (Woolcock et al., 2011);
also, the Alu RNAs that accumulate in DICER1 deficiency may
modulate translation (Ha¨sler and Strub, 2006) or repress gene
and miRNA transcription (Yakovchuk et al., 2009). In conclusion,
there is great potential for DICER1 to mediate the intersection
of multiple AMD-associated mechanisms of disease (Figure 4).
To be sure, there is no shortage of future research directions
that revolve around the broad-reaching functions of DICER1.
As the mechanistic role of DICER1 and Alu RNA in AMD are
deciphered, neutralization of Alu RNA (e.g., antisense oligonu-
cleotides), restoration of DICER1 levels (e.g., gene replacement
therapy), or pharmacological targeting of the downstream
MyD88 effector (e.g., small molecule or siRNA) are possible
strategies to address this imbalance in AMD pathophysiology.
Environmental Risk Factors
Smoking is the most consistently documented modifiable risk
factor for developing AMD. Smoking also confers the greatest
numerical risk for AMD: smokers are 2–3 times as likely than
nonsmokers to develop AMD (Chen et al., 2011), and smoking
cessation reduces the risk of developing AMD (Thornton et al.,
2005). Several nutritional deficiencies are associated with AMD
risk. Low dietary intake of anti-oxidants is associated with
increased AMD risk, and a large clinical trial reported that
high-dose antioxidant supplementation modestly reduced
AMD progression (Age-Related Eye Disease Study Research
Group, 2001). However, even these benefits are restricted to
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a recent epidemiologic study, omega-3 fatty acid (FA) intake was
associated with a lower risk of AMD (Christen et al., 2011). The
protective effect of statins on AMD is not well established and
would require long-term prospective interventional studies to
confirm its relevance to AMD pathogenesis. Lifetime exposure
to sunlight is not consistently associated with AMD. Ongoing
clinical trials will assess the potential benefit of various nutritional
supplements for treatment of AMD.
Genetics
The last 15 years of gene hunting have provided a foundation for
population-based studies in dry AMD. However, the lack of
breakthroughs in diagnostic or therapeutic strategies, or even
in fundamentally advancing pathogenetic insights, has been
disappointing. In contrast, over the same period of time, five
different therapies were developed and are now in use for neo-
vascular AMD.
Genome-wide association studies (GWAS) represent one
prevailing approach in AMD research that has been used in
attempt to predict risk of disease, understand pathogenesis,
and identify potential therapeutic targets. GWAS ascribe
specific gene variations to a group of people that have a
common disease phenotype (e.g., those with or without
AMD). GWAS have indeed identified several genetic loci, which
harbor genetic variants known as single nucleotide polymor-
phisms (SNPs) that associate with an increased risk of AMD.
An extensive review of genetic variation in AMD has been pub-
lished elsewhere (Patel et al., 2008).
Risk Assessment
In contrast to most diseases in which common risk variants do
not explain the majority of genetic heritability (Goldstein, 2009;
Manolio et al., 2009; McClellan and King, 2010; Paynter et al.,
2010), aggregate gene variation accounts for a bulk of the
statistical risk of AMD (Edwards et al., 2005; Klein et al., 2010;
Scholl et al., 2009) or CNV (Hageman et al., 2005). In addition,
other models may use genetic information to predict progres-
sion from early (asymptomatic, no vision loss) to advanced
(symptomatic, vision loss) AMD (reviewed in Charbel Issa
et al., 2011), although they do not predict disease progression
once advanced AMD has developed (Klein et al., 2010; Scholl
et al., 2009). Also, since there are no approved treatments for
GA, any analysis of factors that increase GA risk or progression,
including information gleaned from AMD biomarkers (Gu et al.,
2009; Guymer et al., 2011), provides therapeutically inactionable
information at present.
Variation in multiple complement system genes (Bird, 2010;
Bradley et al., 2011) is one of the most consistent statistical
associations with AMD risk. It bears noting that the discovery
of complement dysregulation in AMD based on biochemical
approaches (Baudouin et al., 1992; Hageman et al., 2001; John-
son et al., 2001) predated the identification of sequence varia-
tions in complement genes (Edwards et al., 2005; Hageman
et al., 2005; Haines et al., 2005; Klein et al., 2005).
The complement gene variant conferring the greatest quanti-
tative statistical AMD risk is factor H (CFH). CFH inhibits a key
activation step in complement activation, thereby reducing
complement-induced host cell damage and inflammation. Still,there exists a very low sensitivity and specificity in terms of
using genetic variation in CFH alone to determine AMD risk. In
fact, when taking into consideration disease prevalence, the
positive predictive value of genetic variation to assess AMD
risk is anemic, even when multiple genetic loci are considered
(Jakobsdottir et al., 2009).
Nevertheless, the predictive power of AMD risk assessment
can be augmented greatly by considering genetic information
from multiple loci in combination with epidemiologic and envi-
ronmental risk factors. Indeed, many nongenetic, environmental
risk factors for AMD have been identified, and for further dis-
cussion on this topic the reader is directed to excellent and
comprehensive reviews (Ambati et al., 2003a; Chakravarthy
et al., 2010; Krishnadev et al., 2010). In addition, onset and affec-
tion status of the fellow eye can be strongly influenced by an
aggregated genetic risk (Chen et al., 2011). Next-generation
sequencing technologies combined with rigorous biological
definition of mechanistic implications of the identified variants
are likely to yield more valuable insights both into disease path-
ogenesis and rational development of novel diagnostics and
therapeutics in the coming decade.
Current Therapeutic Prospects
Here, we will review the frontline experimental approaches and
potential future directions for the treatment of AMD. We will
also discuss the mechanistic justification of these interventions.
Targeting Complement in GA
Complement inhibition as a therapeutic strategy represents the
culmination of numerous research articles that focus on the
role of complement in AMDpathogenesis. Although complement
inhibition suppresses CNV in animal models of wet AMD, it has
not been shown to ameliorate dry AMD in vivo. Indeed, there
are robust human data that lead one to question the value of
complement inhibition for dry AMD. First, SNPs in complement
genes do not predict progression of dry AMD (Klein et al.,
2010; Scholl et al., 2009). Second, complement deposition is
not prominent in GA eyes (J.A., unpublished data; Hageman,
personal communication). Finally, RPE cells are extremely resis-
tant to complement-induced cell death (J.A., unpublished data;
Dean Bok, personal communication) except when their rich
cache of negative complement regulators is simultaneously
antagonized or depleted (Lueck et al., 2011). However, such
strategies may not be representative of the disease state as
there is no apparent reduction in expression of these negative
regulators with aging or in AMD (Lincoln Johnson, personal
communication). Indeed, in a recent clinical trial, there was no
benefit of an anti-C5 antibody in reducing drusen or expansion
of GA (C.A.A.G. Filho et al., 2012, Association for Research in
Vision and Ophthalmology, conf.). The rationale for ongoing
clinical trials investigating complement inhibition appears to
rest primarily with genetic association; robust preclinical exper-
imentation is still required to resolve the ostensibly therapeutic
effect of complement inhibition for dry AMD.
Targeting Complement in CNV Treatment
With respect to complement inhibition for the treatment of CNV,
this strategy may have a dual mechanism of action: reduction
in secretion of VEGF-A by RPE or inhibiting the retinal infiltra-
tion of proangiogenic leukocytes (Nozaki et al., 2006). SeveralNeuron 75, July 12, 2012 ª2012 Elsevier Inc. 33
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CNV in animal models of disease (Bora et al., 2007; Nozaki
et al., 2006; Rohrer et al., 2009). There are plans to test the
safety of one complement inhibitor (POT-4) in a phase I clinical
trial in patients with CNV (NCT 00473928). In summary,
complement inhibitors suppress CNV in animal models of
disease, thus supporting clinical investigation of their use in
humans.
TLR3 in GA and CNV: A Precarious Target
A SNP in the gene coding for the dsRNA sensor toll-like
receptor 3 (TLR3) was initially reported to be associated with
protection against developing GA (Yang et al., 2008). However,
this association was not confirmed in other studies. Genetic
association or not, TLR3 knockout mice are protected against
RPE degeneration caused by exogenous dsRNA (Kleinman
et al., 2012) or by accumulation of all-trans retinaldehyde
(Shiose et al., 2011). Certain viruses contain dsRNA genomes,
while other viruses may elaborate dsRNA intermediates during
their replication cycle. Therefore, it is tempting to speculate
that there might be a viral etiology of GA—an underinvestigated
area of research in AMD. Another potential source of TLR3
activation in GA could be endogenous mRNA (Kariko´ et al.,
2004). On the other hand, it is important to recognize that
TLR3 stimulation causes CNV suppression (Kleinman et al.,
2008); therefore, although modulation of TLR3 activity shows
promise in treating either dry or wet AMD, it also risks potential
exacerbation of the other form.
Autophagy
Autophagy-promoting molecules may also provide a beneficial
therapeutic effect for dry and wet AMD. One experimental
model showed that the classic autophagy inducer rapamycin
inhibits angiogenesis sprouting and VEGF-A production by
RPE cells (Stahl et al., 2008). Also, in a small pilot study, systemic
rapamycin reduced the number of anti-VEGF-A injections
required to treat CNV; although the authors attributed this
effect to immune suppression, it is possible that rapamycin
also directly inhibited endothelial cell proliferation and also
modulated RPE secretion of VEGF-A (Nussenblatt et al., 2010).
Rapamycin was used in the EMERALD clinical trial (Phase II,
NCT 00766337), which included of ranibizumab plus rapamycin
for CNV. However, this study was terminated and we are not
aware of any published results.
In theory, targeting autophagy appears to be a promising
avenue for future endeavors in AMD research. However, there
are several stipulations to this strategy. First, induction of
autophagy would require careful dosing and timing. Under
some circumstances, especially in feeble or dying cells, autoph-
agy can cause cell death (Kourtis and Tavernarakis, 2009).
Furthermore, since there is some crosstalk between autophagic
and apoptotic machinery, healthier cells may also undergo
apoptosis if they register a strong enough proautophagic signal
(Maiuri et al., 2007). In light of these considerations, one might
expect autophagy induction to be a reasonable treatment for
early macular degeneration, when signs of RPE damage are
just beginning. On the other hand, if the RPE is damaged past
a critical point, such as in the later stages of AMD, autophagy
might cause cell death and thereby exacerbate the disease.
Indeed, this concept has been demonstrated in an animal34 Neuron 75, July 12, 2012 ª2012 Elsevier Inc.model of AD (Majumder et al., 2011); in the case of autophagy,
timing is of the essence. The global immune-modulatory effect
of mTOR inhibition on retinal health would also be important
to discern before its clinical investigation.
Immunovascular Modification
Whereas anti-VEGF-A treatment is directly antiangiogenic to the
CNV vasculature, the mechanisms of immune cell contribution
to CNV are less clear. Addressing the functional effect of anti-
VEGF-A therapy on specific immune cell types will be essential
in understanding the proposed inflammatory link to CNV. The
reader is directed to further discussion of the need for strategies
to target both vascular and extravascular components in
treatment of CNV (Spaide, 2006).
If CNV is immune driven, then another pertinent question
is: Does dampening the immune response suppress CNV?
Although anti-VEGF therapy is the current standard of care for
CNV, the use of steroids to inhibit the immune system was
once a frontline clinical option. Triamcinolone is one example
of a steroid that was once widely used for treatment of CNV
but does not provide long-term improvement in vision (reviewed
in Becerra et al., 2011). Nevertheless, triamcinolone and other
steroids are still sometimes used as adjunct therapies because
they can reduce the frequency of other treatments in tandem.
There are some case reports and small-scale studies showing
that other immunosuppressants (e.g., methotrexate, nonste-
roidal anti-inflammatory drugs) might somewhat ameliorate
CNV (reviewed here: Wang et al., 2011b), although larger studies
are required to validate these findings.
Treatment of CNV: Beyond VEGF-A
The immune and vascular systems that feed CNV are inter-
twined, and modulation of either shows clinical benefit for
CNV. Anti-VEGF-A therapy is currently the most effective single
agent for the majority of CNV patients. A better understanding
of specific immune effectors will be important in designing
improved immune-modifying CNV therapy. Future experimen-
tation in humans is required to confirm the potential of comple-
ment inhibition or anti-oxidants in treating CNV. All of these
aforementioned interventions hold a common link in that they
somehow dampen the immunovascular axis of disease. But
might there be an intervention that affects the CNV vasculature
with minimal effect on the immune component? In light of the
potential efficacy-reducing immune modulation resulting from
anti-VEGF-A therapy, a specific vascular-acting molecule would
be a novel therapeutic target in CNV.
In fact, it seems that such a target exists. The eotaxin family of
chemokines and their receptor CCR3 are found in human CNV
specimens but not in the undiseased choroid (Takeda et al.,
2009). Despite the known role of eotaxins in eosinophil and
mast cell chemotaxis, these eotaxins did not promote immune
cell migration to the retina in this system; instead, they acted
on the endothelial receptor CCR3, which in turn stimulated
angiogenesis (Takeda et al., 2009). CCR3 inhibition was slightly
more effective than anti-VEGF-A in suppressing CNV in a mouse
model of disease. Furthermore, CNV suppression occurred
without altering levels of VEGF-A, although more subtle interac-
tions between these pathways have been identified (Wang et al.,
2011a). Thus, unlike anti-VEGF-A or anti-inflammatory treat-
ment, blocking the eotaxin-CCR3 axis in CNV might avoid major
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ings are buttressed by other studies validating the efficacy of
CCR3 targeting in laser-induced CNV (T. Mizutani, et al., 2011,
Association for Research in Vision and Ophthalmology, conf.),
the overexpression of CCR3 and its ligand in a spontaneous
mouse model of CNV (N. Nagai, et al., 2011, Association for
Research in Vision and Ophthalmology, conf.), and by studies
showing increased circulating eotaxins in AMD patients (Mo
et al., 2010). Looking forward to chemokine-targeting therapy,
bertilimumab, a monoclonal antibody targeting eotaxin-1, is
slated for clinical trials in CNV.
It is also important to investigate disease mechanisms other
than VEGF-A in CNV, especially in light of mechanistic findings
that VEGF-A has a physiologic cytoprotective role in the retina,
and that quenching or altering VEGF expression can be toxic
to multiple cell types in rodent retina (Ford et al., 2011; Murakami
et al., 2010; Nishijima et al., 2007; Saint-Geniez et al., 2008;
Takeda et al., 2009). Recently, evidence has accumulated to
support the concept that anti-VEGF-A therapy can contribute
to physiological alterations in the retinal vasculature in the
short-term (Papadopoulou et al., 2009; Sacu et al., 2011) and
frank RPE toxicity in the long-term (R.B. Bhisitkul, 2011, UCSF
Ophthalmology Update, conf.; R.B. Bhisitkul et al., 2012, Associ-
ation for Research in Vision and Ophthalmology, conf.).
Retinal Replacement
An alternative approach to restoring the health of moribund
RPE cells is to replace them. Indeed, RPE cell transplant with
fetal neural tissue or human embryonic stem cell (hESC)-
derived RPE-like cells is the focus of current clinical trials
(NCT00346060; NCT01344993). Following implantation of
hESC-derived RPE cells into mice, increased eye movement to
light stimulus was reported (Lu et al., 2009). In contrast to
the foreseeable complications of autophagy-induction in late
AMD, replacing the dying RPE with sprightly implanted cells
might be preferable in such cases of advanced disease. RPE
cell replacement may even complement efforts to perform
retinal transplant, which is the transfer of the neural retina from
areas of dying RPE cells to healthier regions (Sheridan et al.,
2009; Zarbin, 2008). An alternative approach to retinal replace-
ment is the Argus II ‘‘bionic eye,’’ recently approved for use in
Europe and awaiting US FDA approval. Argus II is a microchip
implanted in the retina that transmits environmental light stimuli
to the brain via the optic nerve, thus providing some visual, albeit
artificial, relief to a small fraction of treated patients (Humayun
et al., 2012). If the pharmacologic rescue of near-deteriorated
cells remains exceedingly inactionable, then perhaps cell
replacement or microchip implants will arrive at the forefront of
therapeutic hope.
Conclusions and Outlook
Ostensibly, the numerous influences that underlie AMD provide
multiple potential targets for disease treatment (Ambati et al.,
2003a; Bird, 2010). However, despite their apparent heteroge-
neity, these pathways are highly redundant and can produce
similar pathologic effects. Therefore, any therapeutic interven-
tion that addresses an isolated injurious mechanism is unlikely
to counter the convergence of parallel conduits.Looking toward the future of AMD therapy, an emerging
paradigm diverges from the conventional approach of prevent-
ing retinal dysfunction and death. Instead, empowering retinal
health in spite of injury, rather than attempting to eliminate
numerous overlapping insults, deserves appreciable investiga-
tion in AMD prevention and treatment. Modulating or enhancing
specific RPE coping mechanisms, rather than attempting to
remove modify heterogeneous barrage of insults, is an intriguing
conceptual scaffold on which to base future therapeutic devel-
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